| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development expenses | $281K+103.2% | $138K-1.0% | $140K-47.7% | $267K |
| General and administrative expenses | $1.5M+7.9% | $1.4M-28.5% | $1.9M-45.1% | $3.5M |
| Total operating expenses | $1.8M+16.7% | $1.5M-26.6% | $2.1M-45.3% | $3.7M |
| LOSS FROM OPERATIONS | -$1.8M-16.7% | -$1.5M+26.6% | -$2.1M+45.3% | -$3.7M |
| LOSS, BEFORE INCOME TAX | -$1.8M-16.7% | -$1.5M+26.6% | -$2.1M+45.3% | -$3.7M |
| NET LOSS | -$1.8M-16.7% | -$1.5M+26.6% | -$2.1M+45.3% | -$3.7M |
| Net loss per share attributable to common shareholders, basic | -$0.12+7.7% | -$0.13+27.8% | -$0.18+47.1% | -$0.34 |
| Net loss per share attributable to common shareholders, diluted | -$0.12+7.7% | -$0.13+27.8% | -$0.18+47.1% | -$0.34 |
| Weighted average common shares outstanding used in computing net loss per share attributable to common shareholders, basic | $15233501.00+33.2% | $11435362.00+0.8% | $11346535.00+3.0% | $11016165.00 |
| Weighted average common shares outstanding used in computing net loss per share attributable to common shareholders, diluted | $15233501.00+33.2% | $11435362.00+0.8% | $11346535.00+3.0% | $11016165.00 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.